Drugs / ACM-001.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06028321 | Nov 2021 → Jun 2022 | hypoproteinemia, hypercatabolic | Actimed Therapeutics Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07101939 Comparator | Jun 2025 → Mar 2027 expected | muscular atrophy, obesity disorder | Actimed Therapeutics Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-12-13 | Actimed Therapeutics Ltd | Results Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle actimedtherapeutics.com ↗
The study met all pre-defined endpoints, demonstrating that S-pindolol benzoate has predictable pharmacokinetics up to a dose of 15 mg twice daily, with low inter-subject variability after single and multiple doses. |
| 2023-09-07 | Actimed Therapeutics Ltd | Regulatory Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia actimedtherapeutics.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACM-001.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06028321 ↗ |
| Known as | S-Pindolol Benzoate | “Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.” PMID 39665235 ↗ Dec 2024 |
| Action | Activate | “increased anabolism through partial β2 receptor agonism” PMID 39665235 ↗ Dec 2024 |
| Route | Oral | “ACM-001.1 immediate release tablets for oral use” NCT06028321 ↗ |